Skip to content
General News, Medical Health Aged Care

Public Hearing for Amendments to the International Health Regulations (IHR)

Parliament of Australia 2 mins read

The Joint Standing Committee on Treaties will hold a public hearing on 23 October 2025 for its inquiry into the Amendments to the International Health Regulations (2005). This inquiry lapsed on 28 March 2025, with the prorogation of Parliament, and was re-referred to the Committee for continued consideration in the 48th Parliament.

The inquiry will consider the amendments to the International Health Regulations (IHR) which were unanimously adopted at the 77th World Health Assembly in Geneva on 1 June 2024. At the public hearing, the Committee will examine how the Amended IHR define countries’ obligations and rights in responding to public health emergencies of international concern, and their focus on pandemic prevention, preparedness, and response. This includes provisions which increase Member States’ access to essential health products and financing required in public health emergencies.

Committee Chair, Ms Lisa Chesters MP, said, ‘The inquiry will consider how the Amendments to the International Health Regulations aim to facilitate greater cooperation between Australia, and our international partners, in future high-risk health events, by encouraging collective action, and clarifying the rights and responsibilities of Member States during public health emergencies.’

The Committee will hear evidence from:

  • The Department of Health, Disability and Ageing
  • The Department of Foreign Affairs and Trade
  • Australian Medical Professionals Society
  • Australians for Science and Freedom
  • Australian Multicultural Action Network
  • Australian Institute for Infectious Diseases.

Further information is available on the Committee’s website.

Public hearing details

Date: Thursday 23 October 2025
Time: 14:45 to 17:00
Location: Committee Room 2R1, Parliament House Canberra and online

The hearing will be broadcast live at aph.gov.au/live.

Media inquiries

Ms Lisa Chesters MP, Chair 
Korey Fernando, Diary Manager
[email protected]
(03) 5443 9055 

For background information

Committee Secretariat
02 6277 4002
[email protected]

For more information about this Committee, you can visit its website. On the site, you can make a submission to an inquiry, read other submissions, and get details for upcoming public hearings. You can also track the Committee and receive email updates by clicking on the blue ‘Track Committee’ button in the bottom right hand corner of the page.

 

More from this category

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • General News, Religion
  • 06/12/2025
  • 21:45
Anglican Diocese of Adelaide

Bishop Bradly Billings elected as 11th Archbishop of Adelaide

MEDIA RELEASE 6 December 2025 Bishop Bradly Billings elected as 11th Archbishop of Adelaide The Anglican Diocese of Adelaide is pleased to announce the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.